Showing 1 - 5 results of 5 for search 'Harry Miao', query time: 0.03s Refine Results
  1. 1
    P1204: AXICABTAGENE CILOLEUCEL VEIN-TO-VEIN TIME IN TRIAL OR REAL-WORLD SETTINGS VS OTHER CAR T-CELL THERAPIES FOR RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS

    P1204: AXICABTAGENE CILOLEUCEL VEIN-TO-VEIN TIME IN TRIAL OR REAL-WORLD SETTINGS VS OTHER CAR T-CELL THERAPIES FOR RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: A SYSTEMATIC LITERATUR... by Frederick Locke, Michael T. Hemmer, Steve Kanters, Michael J. Zoratti, Zhen-Huan Hu, Harry Miao, Shilpa Shahani, Clare Spooner, Christine Fu, Anik Patel, Hairong Xu, Marcelo Pasquini

    Published 2023-08-01
    Get full text
    Article
  2. 2
    S223: REAL-WORLD EARLY OUTCOMES OF AXICABTAGENE CILOLEUCEL FOR RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

    S223: REAL-WORLD EARLY OUTCOMES OF AXICABTAGENE CILOLEUCEL FOR RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA by Caron Jacobson, Michael T. Hemmer, Zhen-Huan Hu, Matthew Frank, Leslie Popplewell, Nausheen Ahmed, Yi Lin, Timothy Best, Sara Beygi, Harry Miao, Christine Fu, Fang Sun, Hairong Xu, Marcelo Pasquini

    Published 2023-08-01
    Get full text
    Article
  3. 3
    PB2346: ZUMA-24: A PHASE 2, OPEN-LABEL, MULTICENTER STUDY OF AXICABTAGENE CILOLEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA GIVEN WITH CORTICOSTEROIDS IN THE OUTPATIENT SETTING

    PB2346: ZUMA-24: A PHASE 2, OPEN-LABEL, MULTICENTER STUDY OF AXICABTAGENE CILOLEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA GIVEN WITH CORTICOSTEROIDS IN THE OU... by Lori Leslie, Michael Tees, Ian W. Flinn, Tulio Rodriguez, John H. Baird, Abhinav Deol, Monica Mead, Carlos Bachier, Aaron P. Rapoport, Brian Mcclune, Daanish Hoda, Miguel-Angel Perales, Yan Zheng, Simone Filosto, Madison Davis1, Harry Miao, Jenny J. Kim, Olalekan O. Oluwole

    Published 2023-08-01
    Get full text
    Article
  4. 4
    PB2319: ZUMA-23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST-LINE THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL LYMPHOMA

    PB2319: ZUMA-23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST-LINE THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL LYM... by Jason Westin, Caron Jacobson, Julio C Chavez, Anna Sureda, Franck Morschhauser, Bertram Glass, Michael Dickinson, Andrew J. Davies, Ian W. Flinn, David Maloney, Martine Chamuleau, Michael Tees, Allen Xue, Shilpa Shahani, Olga Nikolajeva, Janet Kang, Aida Kaplan, Marco Schupp, Harry Miao, Elizabeth Shima Rich

    Published 2023-08-01
    Get full text
    Article
  5. 5
    A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors

    A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors by Dejan Juric, Minal Barve, Ulka Vaishampayan, Desamparados Roda, Aitana Calvo, Noelia Martinez Jañez, Jose Trigo, Alastair Greystoke, R. Donald Harvey, Anthony J. Olszanski, Mateusz Opyrchal, Alexander Spira, Fiona Thistlethwaite, Begoña Jiménez, Jessica Huck Sappal, Karuppiah Kannan, Jason Riley, Cheryl Li, Cong Li, Richard C. Gregory, Harry Miao, Shining Wang

    Published 2024-03-01
    Get full text
    Article

Search Tools: